New interim phase IIa data on simeprevir in combination with other DAAs will be presented at the upcoming EASL AASLD Special Conference
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new clinical data from an ongoing phase IIa study of simeprevir, odalasvir and AL-335, being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), will be presented at the European Association for the Study of the Liver (EASL)/American Association for the Study of Liver Diseases (AASLD) Special Conference entitled “New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure”. The conference will take place in Paris, France, on September 23rd and 24th 2016. The ePoster presentation, entitled “Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection”, will be made on Friday September 23rd. It will include interim data which aims to establish the safety, pharmacokinetics and efficacy (SVR12) of different combination regimens consisting of three directly acting antiviral agents (DAAs), simeprevir, odalasvir, an HCV NS5A inhibitor, and AL-335, a nucleotide inhibitor of the HCV NS5B polymerase, for the treatment of GT 1 HCV infection in eight weeks or less. Further information about the study is available at clinicaltrials.gov/show/NCT02569710.
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 14.00 CET on 11 August 2016.
About Medivir
Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
Tags: